This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Information on adverse event reporting can be found at the bottom of this page.
Committed To Those Affected By Cancer
Pfizer Oncology has a longstanding commitment to helping those affected by cancer. By placing patients and collaboration at the centre of everything we do, we believe we can have a meaningful impact on the lives of cancer patients - both now and in the future.
Our Efforts Against Cancer
Every day, around 1,000 people are diagnosed with cancer in the UK.1 But, thanks to innovative treatments and significant advances in the understanding of the disease, more people than ever are surviving cancer.2
At Pfizer Oncology, we have a portfolio of more than 20 approved innovative cancer medicines and biosimilars across over 30 indications, including melanoma, breast, genitourinary, colorectal, blood and lung cancers.3 Find out more.
We've made meaningful progress - but our work is far from finished. Currently, there are over 200 Pfizer-sponsored Oncology clinical trials ongoing globally, with studies spanning more than 20 different tumour types and subtypes.3 Learn more.
At Pfizer UK, we are proud of our long history of successfully partnering with organisations that share our purpose to deliver the right treatment for each patient at the right time. We also partner with scientists, academics and clinicians, to share knowledge, skills and expertise, with the aim to improve the health and lives of people in the UK and around the world.
Over the past 70 years, we have continued to invest in the UK and are committed to working with the National Health Service (NHS) and other healthcare organisations across the industry, developing solutions to improve the delivery of care and patient outcomes. The NHS has access to over 150 Pfizer medicines and vaccines that are delivered to pharmacies, surgeries, and hospitals across the UK every day.5
We also partner with relevant policy-makers and other stakeholders, driven by our purpose to deliver breakthroughs that could change patients' lives.
Patients are now - more than ever - equipped, informed and empowered to define healthcare in their own terms. At Pfizer, we recognise the importance of harnessing the power of patient experiences to understand what healthcare means to the individual. Through our commitment to working together, we aim to personalise patient care and deliver better healthcare for the people that matter most - patients.
Patient centricity within Pfizer Oncology is a longstanding tradition. Over the years, our team has cultivated relationships with many patient advocates across the world - with the common goals of ensuring health equity and literacy for all, and supporting patient engagement in clinical trials.
In 2019, to expand these efforts and further embed patient insights and experiences into all activities, Pfizer Oncology launched an initiative to create a Patient Centric Ecosystem (POPCE). The initiative ensures a continued focus on patient centricity by engaging and collaborating with advocacy leaders on priority activities identified by advocates. Today, this ecosystem is continuing to yield actionable insights, providing opportunities for information-sharing and partnership across the cancer community.4
At Pfizer, we are relentless in our pursuit of medicines and vaccines that could benefit patients around the world. By 2025, we hope that our medicines will help to treat 225 million people.3
In addition to our medicines, we are also supporting patients through innovative technologies, such as the free ByYourSideTM app, a digital support programme designed specifically to help people living with cancer, as well as their friends and family members. Download ByYourSideTM from the Apple App Store or get it on Google Play.6
In the UK, we are also investing in the future by supporting the scientists of tomorrow through the UK's National Apprenticeship Programme, our undergraduate placement scheme and various STEM (Science, Technology, Engineering and Mathematics) and SIP (Science Industry Partnership) activities.5 Find out more.
Our portfolio of treatments stretches across multiple indications, including breast, genitourinary, blood and lung cancers.
References:
1. International Agency for Research on Cancer (IARC). United Kingdom Factsheet. Available at: https://gco.iarc.fr/today/data/factsheets/populations/826-united-kingdom-fact-sheets.pdf. Last accessed September 2023.
2. Maddams J, Utley M, Møller H. Projections of cancer prevalence in the United Kingdom, 2010-2040. Br J Cancer 2012; 107 (7):1195-202.
3. Pfizer data on file.
4. Pfizer Oncology Patient Centricity Ecosystem: From Launch to Impact. Available at: https://cdn.pfizer.com/pfizercom/Pfizer_APR_WhitePaper_080921.pdf. Last accessed September 2023.
5. Pfizer.co.uk. Pfizer in the UK. Available at: https://www.pfizer.co.uk/our-science/pfizer-uk. Last accessed September 2023.
6. ByYourSide. ByYourSide App. Available at: https://www.byyourside.co.uk/byyourside-app. Last accessed September 2023.
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021